Lv2
118 积分 2023-03-21 加入
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
8天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
13天前
已完结
The complex patent situation regarding antibody Fc engineering
21天前
已完结
AI-accelerated therapeutic antibody development: practical insights
1个月前
已完结
CAR-T cell Therapies for B-cell Lymphoid Malignancies
2个月前
已完结
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
2个月前
已完结
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
2个月前
已完结
Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug Conjugates
3个月前
已完结
Trimming Crystallizable Fragment (Fc) Glycans Enables the Direct Enzymatic Transfer of Biomacromolecules to Antibodies as Therapeutics**
3个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
3个月前
已完结
皖公网安备34019202002308
